Holen Sie sich die Stockscreener-App
20.84
2.62%
2.865
Defiance Trillion Dollar Club Index Etf Aktie (TRIL) Neueste Nachrichten
TRIL ETF Holdings List — BOATS:TRIL - TradingView
Defiance floats ETF tied to firms, digital assets valued above US$1 trillion - Structured Retail Products
TRIL Stock Fund Price and Chart — BOATS:TRIL - TradingView
US ETF launches from 25th September to 2nd October, 2025 - ETF Express
‘$1 Trillion Club’ ETF Offers Investors Exposure to Tech Giants and Bitcoin - The Currency analytics
A new "Trillion Dollar" ETF based on stocks and Bitcoin has appeared in the US. - Happy Coin News
'$1T Club' ETF offers exposure to tech giants and Bitcoin - Bitget
Tron Inc. Shares Tumble 85% From June Peak Amid DAT Market Slump - Decrypt
Defiance ETFs Launches New Trillion-Dollar Assets ETF: U.S. Access to Tech Giants and Crypto-Linked Plays - Blockchain News
SEC No-Action Letter Creates Opening for More Firms to Serve as Crypto Custodians - Decrypt
Ripple CTO David Schwartz to Step Back, Remain on Board as CTO Emeritus - Decrypt
'$1 Trillion Club' ETF Gives Investors Exposure to Tech Giants—And Bitcoin - Decrypt
Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New “Magnificent 7” of Global Markets - GlobeNewswire
TRIL ETF Analysis: Dividends, Returns NASDAQ:TRIL - TradingView
Defiance Launches JEDI – Drone & Modern Warfare ETF: Exposure to Leading Drone and Modern Warfare Companies - GlobeNewswire
Defiance ETFs Launches QLDY, the First ETF to Pay Distributions Twice Weekly * - GlobeNewswire
Defiance’s QTUM – Quantum Computing ETFSurpasses $2 - GlobeNewswire
Sezary Syndrome Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | 4SC AG, Seagen Inc., Merck Sharp & Dohme Corp., Innate Pharma, Trillium Therapeutics, Sec - Barchart.com
Defiance ETFs Launches Leveraged + Income ETFs for AMD (AMDU) and Super Micro Computer (SMCC) - GlobeNewswire
Defiance ETFs Launches Leveraged + Income ETFs for Palantir - GlobeNewswire
Defiance Launches VIXI: Enhanced Long Volatility ETF with Leveraged Short S&P 500 Exposure - GlobeNewswire
How Many Trillium Therapeutics Inc. (TSE:TRIL) Shares Do Institutions Own? - ca.sports.yahoo.com
Relapsing Refractory Multiple Myeloma Pipeline Outlook Report 2025: Key 55+ Companies and Breakthrough Therapies Shaping the Future Landscape - Barchart.com
Relapsing Refractory Multiple Myeloma Pipeline Outlook Report 2025: Key 55+ Companies And Breakthrough Therapies Shaping The Future Landscape - Menafn
Defiance Launches AIPO: The First ETF Focused on AI Power Infrastructure - GlobeNewswire
Weekly ETF Industry Recap: U.S., Europe, and Canada Highlights – July 7-July 11, 2025 - Trackinsight
Pfizer ends Phase 1b/2 trial for final Trillium CD47 drug - Endpoints News
Defiance ETFs Unveils $MST: The First Leveraged MicroStrategy ETF that Seeks to Pay Income Weekly - GlobeNewswire
PD-1 and PD-L1 Inhibitors Market Report- Expansive Coverage on the Profit Sources - openPR.com
CD47 Targeting Therapeutics Market Robust Expansion is expected to 2034 - openPR.com
Defiance Launches $GLDY, Gold Enhanced Options Income ETF - GlobeNewswire
Defiance’s XMAG ETF Outshines S&P 500 Amid “Magnificent 7” - GlobeNewswire
Defiance ETFs' QTUM, Quantum Computing ETF, Earns 5-Star Morningstar Rating and Surpasses $1 Billion in AUM - GlobeNewswire
CD47 Antigen Inhibitors Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight - GlobeNewswire
$QTUM, Defiance Quantum Computing ETF, Surpasses $1 Billion in AUM - GlobeNewswire
Matrix Capital Management Co Reports A 16.5 Pct Passive Stake In Trillium Therapeutics - Reuters
Zentalis Pharmaceuticals Announces Executive Leadership - GlobeNewswire
Defiance Launches XMAG The First ETF Offering Exposure to the S&P 500 Excluding the “Magnificent 7” Tech Giants - GlobeNewswire
As a Billionaire Activist Takes a Stake, Is Now the Time to Buy Pfizer Stock? - The Globe and Mail
Defiance ETFs Announces Monthly Distributions on $QQQY - GlobeNewswire
Quell Therapeutics Appoints Experienced Biopharma Leader - GlobeNewswire
Genexine, EPD Biotherapeutics to merge for new protein degraders - BioWorld MedTech
Genexine Announces Merger with EPD Biotherapeutics to Strengthen Drug Development Pipeline - Business Wire
Pension plans still AWOL as Canadian life-sciences venture capital firms re-up for latest funds - The Globe and Mail
Global Breast Cancer Drug Market for Growth, Projected to Reach USD 12,012.1 Million by 2033 at a 1.1% of CAGR - marketresearchblog.org
Bayer and Vividion Therapeutics to highlight advancing oncology portfolio at AACR 2024 Annual Meeting - Bayer
Defiance Trillion Dollar Club Index ETF (NASDAQ: TRIL)Share Price - intelligentinvestor.com.au
AstraZeneca buys Hamilton-based smart cancer drug maker Fusion Pharmaceuticals for $2-billion - The Globe and Mail
Chronic Myeloid Leukemia Treatment Market On A Growth - GlobeNewswire
Pfizer to acquire Trillium in $2.3bn deal - BioProcess International
Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment - PR Newswire
Joseph Tucker, PhD's Profile Page - Technology Networks
Ozempic maker Novo Nordisk bulks up on weight loss drugs, buying Montreal’s Inversago for $1-billion - The Globe and Mail
Ratio Therapeutics, In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging - PR Newswire
Her2 Inhibitors Market Seen Soaring 7.2% Growth to Reach USD 23305.51 Million by 2030, Projects Univdatos Market Insights - UnivDatos
Bellus shareholders approve US$2-billion takeover by GSK; deal set to close this month - The Globe and Mail
Novartis buys Chinook for US$3.2-billion, latest in string of big exits for Canadian biotechs - The Globe and Mail
GSK’s $2-billion purchase of Bellus delivers second big exit for Montreal’s Bellini family - The Globe and Mail
Jan Skvarka, former Trillium CEO, on Driving a Turnaround - Timmerman Report
H1 2022 Healthcare and Life Sciences in North America: Market Insights - NAI500
Medexus Pharma: Bottom 25 Performing Stocks Year-to-Date on TSX (MDP) - The Globe and Mail
Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors - citybiz
Autobahn Therapeutics raises funds to advance ABX-002 for treatment-resistant depression - BioWorld MedTech
Pfizer in advanced talks to buy firm making sickle cell drugs - PM News Nigeria
Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion, Wall Street Journal reports - Reuters
Doxorubicin Market Revenue to Cross $1,983.40 million by - GlobeNewswire
DEM BioPharma: exploring ‘don’t eat me’ white space beyond CD47 - biocentury.com
DEM BioPharma Launches with $70 Million Financing - Business Wire
Ratio Therapeutics emerges with $20M financing, taking mathematical approach to radiopharmaceuticals - BioWorld MedTech
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors - Quantisnow
Ratio Therapeutics Launches to Discover and Drive Early Clinical Development of Best-in-Class Targeted Radiopharmaceuticals for Treatment of Cancers - PR Newswire
Global Small-cell Lung Cancer Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - GlobeNewswire
0.50%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):